Intrinsic to the survival and proliferation of cancer cells is their ability to subvert or develop resistance to chemotherapy drugs. Traditional proteolysis targeting chimeras, or PROTACs, have sought to harness the cell’s natural recycling machinery—the ubiquitin–proteasome system—to tag and degrade deleterious proteins. However, conventional PROTACs rely on a multistep tagging mechanism that begins with the attachment of ubiquitin molecules to the target protein, a process fraught with inefficiencies and variabilities dependent on specific cellular contexts. These limitations have inspired the search for alternative, more direct methods of inducing protein degradation.

The ubiquitin–proteasome pathway acts as a fundamental cellular waste disposal system, where damaged or superfluous proteins are marked with ubiquitin tags. These tags act as molecular signals, directing the proteins toward the proteasome—the cellular organelle responsible for their breakdown and recycling. Many pathological conditions, including cancer, exploit or evade this system, presenting both hurdles and opportunities for therapeutic intervention. The research spearheaded by Bernat Crosas and his team sought to circumvent the often-inefficient ubiquitination step, proposing instead a direct delivery mechanism to the proteasome.

In this novel strategy, the researchers engineered small molecule chimeras akin to PROTACs but with an innovative twist: they bypass the ubiquitin tagging entirely, directly guiding tumor-relevant proteins to the proteasome for degradation. The targeted proteins include IMPDH2, a crucial enzyme in nucleotide biosynthesis and cell replication, whose dysregulation is tightly linked to tumor advancement, and CERT1, a lipid transporter protein implicated in the regulation of tumor cell death. This direct targeting approach leverages the proteasome-associated protein USP14, a regulator of proteasome activity, to serve as the docking point for the chimeric molecules.

By binding with high affinity to the target proteins and simultaneously to USP14, these small molecules act as molecular bridges, ushering the proteins straight to the proteasome’s degradation machinery. This method facilitates a streamlined, rapid clearance of proteins essential to tumor growth and survival, effectively crippling the cancer cells’ ability to multiply or evade programmed cell death pathways such as apoptosis. Unlike traditional PROTACs, this approach minimizes reliance on the ubiquitin-proteasome axis’s intermediate steps, thereby mitigating points of failure and inefficiency.

Experimental models using cancer cell lines have demonstrated compelling efficacy of these novel chimeric molecules. Notably, the research revealed that degradation of CERT1 sensitizes tumors to chemotherapy agents, suggesting the restoration of drug susceptibility in resistant cancer types. Resistance to chemotherapy poses a significant clinical challenge, with strikingly high prevalence rates—from 60% to 90% in some carcinomas—and often heralds poor patient prognoses, especially in metastatic disease. This novel approach holds promise to circumvent these resistance mechanisms, potentially rejuvenating the effectiveness of existing chemotherapy regimens.

In discussing the implications, Bernat Crosas emphasized the transformative potential of this technology: by redirecting cellular waste disposal pathways more efficiently, it opens exciting therapeutic avenues where targeted degradation can be tailored to specific proteins driving disease progression. Moreover, the modularity of these chimeric molecules allows for customization to target a broader spectrum of pathological proteins beyond those studied, anticipating applications not only in oncology but also in other diseases defined by aberrant protein function.

The current phase of the research focuses on refining these molecules to enhance their specificity and potency, alongside extensive testing in more physiologically relevant models. This progression is critical to transition from proof of concept to clinical translation, offering a new weapon in the oncologist’s arsenal against chemoresistance. Furthermore, understanding the detailed molecular interactions between these chimeras, target proteins, and proteasomal regulators will inform future design iterations, potentially improving therapeutic windows and minimizing off-target effects.

This innovative work reflects a significant milestone in the realm of targeted protein degradation technologies, expanding beyond established paradigms to harness the proteasome’s full potential more directly and effectively. As the ubiquitin-independent degradation pathways gain traction, they provide a complementary and possibly superior route for eradicating proteins that standard therapies struggle to neutralize. The revolutionary nature of these findings is poised to inspire a rethinking of drug development strategies focused on protein homeostasis and degradation.

In essence, this research illustrates an elegant exploitation of the cell’s intrinsic proteolytic machinery, turning the proteasome into a highly specific and efficient executor of therapeutic protein turnover. The deliberate modulation of proteasomal activity through USP14 targeting and direct substrate delivery represents a conceptual leap with substantial implications, heralding a new class of anticancer agents potentially capable of overcoming drug resistance and improving patient outcomes.

Notably, the funding sources, including the Spanish Ministry of Science, Innovation and Universities, alongside the European Union’s Next Generation funds channeled through the CSIC Global Health Platform and the Government of Catalonia, highlight the strategic importance ascribed to this line of investigation. This underscores robust institutional and governmental support aimed at addressing critical challenges in global health through cutting-edge science.

As the biomedical community continues to explore and optimize protein degradation technologies, these findings emphasize the importance of multidisciplinary collaboration, marrying synthetic chemistry, molecular biology, and pharmacology. The promising preclinical outcomes presented by the CSIC team resonate as a beacon for future endeavors aimed at transforming incurable cancers into manageable conditions through precision molecular interventions.

The study, published in the reputed journal Nature Communications, stands as a compelling testament to the constant evolution of therapeutic modalities. It invites further exploration into ubiquitin-independent mechanisms, challenging researchers to expand the molecular toolkit available for targeted degradation. Ultimately, this discovery could redefine therapeutic strategies not only in cancer but across a broad spectrum of diseases characterized by aberrant proteins refractory to conventional treatment.

Subject of Research: People

Article Title: Expanding the targeted protein degradation approach with small molecule chimeras directed to the 26S proteasome

News Publication Date: 28-Mar-2026

Web References: http://dx.doi.org/10.1038/s41467-026-71132-5

Keywords: Proteasomal degradation, targeted protein degradation, PROTACs, chemotherapy resistance, ubiquitin–proteasome system, IMPDH2, CERT1, USP14, cancer therapeutics

Esophageal cancer, characterized by its high mortality rate, remains a major health concern globally. This malignancy primarily manifests in two forms: squamous cell carcinoma and adenocarcinoma. Understanding the cellular and molecular underpinnings of these cancers is essential for developing effective treatment options. The complexity of esophageal cancer further escalates as it often presents at advanced stages, complicating early detection and intervention.

Integral to understanding cancer biology is the ubiquitin-proteasome system (UPS), which is responsible for protein degradation and regulation within the cell. Inhibition or malfunction of this system can lead to the accumulation of oncogenic proteins, fostering tumor growth and survival. In this context, ubiquitin-specific protease 1 (USP1) has emerged as a key player. By deubiquitinating target proteins, USP1 can modulate their stability and activity, making it a molecule of interest in cancer research.

In the study, the authors focus on the role of USP1 in relation to CDC25A, a dual-specificity phosphatase that plays a crucial role in cell cycle regulation. CDC25A functions to activate cyclin-dependent kinases (CDKs), which are essential for the progression through various phases of the cell cycle. The dysregulation of CDC25A is often observed in different cancers, including esophageal cancer, suggesting its involvement in oncogenic processes.

Through experimental validation, the researchers elucidate the function of USP1 in stabilizing CDC25A by removing ubiquitin moieties from it. This is significant, as stabilized CDC25A can, in turn, enhance the expression of CDK1, a cyclin-dependent kinase that drives the transition from the G2 phase to mitosis. The interplay among USP1, CDC25A, and CDK1 creates a feedback loop that significantly influences cell proliferation and tumor growth.

The findings of this research not only enhance our understanding of esophageal cancer but also highlight potential therapeutic targets. By inhibiting USP1, it may be possible to decrease CDC25A levels, leading to reduced CDK1 activity and, consequently, hindered cancer cell proliferation. Such targeted therapeutic strategies could transform the current landscape of esophageal cancer treatment, which is often limited to surgery, chemotherapy, and radiation.

Moreover, the implications of the study extend beyond esophageal cancer. The pathways involving USP1, CDC25A, and CDK1 are conserved across various cancer types, positioning USP1 as a potential pan-cancer target. By further exploring these molecular interactions, researchers could unveil new insights into the treatment of other malignancies that share similar regulatory pathways.

The study by Feng and colleagues is a testament to the importance of molecular biology in elucidating the complexities of cancer. It serves as a reminder that understanding the intricate signaling networks within cells can pave the way for innovative treatment modalities. As the research community continues to unravel the mechanisms driving cancer progression, the promise of targeted therapies becomes ever more attainable.

The authors emphasize that further studies are needed to validate their findings in clinical settings and to evaluate the potential side effects of USP1 inhibition. It is critical to understand whether the therapeutic targeting of USP1 would affect normal cells as well, and if so, how this could be managed in treatment regimens.

As this research gains traction, the interest in identifying and developing USP1 inhibitors could escalate. Pharmaceutical companies may begin to explore compounds that can target USP1 effectively. The challenge will lie in ensuring that such inhibitors are selective, minimizing off-target effects while maximizing therapeutic efficacy.

As we look to the future, the integration of molecular insights from studies like this into clinical applications holds promise for improving patient outcomes in esophageal cancer. With the ongoing advancements in cancer therapeutics and increased understanding of tumor biology, the vision of precision medicine becomes increasingly viable.

Feng, Yan, and Ge’s research not only marks a significant milestone in cancer biology but also ignites hope for patients battling esophageal cancer. By targeting the underlying molecular mechanisms driving tumor progression, we may one day develop effective treatments that significantly improve survival rates and quality of life for those affected by this dire illness.

In conclusion, the intersection of molecular biology and cancer therapy continues to evolve, and the research conducted by Feng and colleagues serves as a crucial contribution to this dynamic field. The work underscores the necessity for ongoing investigation into cancer pathways, with the collective aim of translating these findings into clinical success.

Subject of Research: The regulatory role of USP1 in esophageal cancer, focusing on CDC25A deubiquitination and CDK1 expression.

Article Title: USP1 regulates esophageal cancer progression through CDC25A deubiquitination to regulate CDK1 expression.

Article References: Feng, J., Yan, Z. & Ge, J. USP1 regulates esophageal cancer progression through CDC25A deubiquitination to regulate CDK1 expression. 3 Biotech 16, 47 (2026). https://doi.org/10.1007/s13205-025-04663-1

Image Credits: AI Generated

DOI: https://doi.org/10.1007/s13205-025-04663-1

Keywords: USP1, esophageal cancer, CDC25A, CDK1, ubiquitin-proteasome system, targeted therapy, cancer biology, molecular mechanisms.